OCEA
Ocean Biomedical, Inc.0.0010
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
232.37KP/E (TTM)
-Basic EPS (TTM)
-0.91Dividend Yield
0%Recent Filings
8-K
Nasdaq delisting confirmed
Ocean Biomedical faces Nasdaq delisting after the board declined to review the Listing Council's May 15, 2025 decision, triggering removal procedures under Rule 5830 effective from July 31, 2025 notification. Director Michael Petersen and CFO Jolie Kahn resigned on August 31 and August 5, respectively, without disagreements over operations. Yet the company presses on with its power and cryptocurrency strategies. Delisting heightens trading risks for investors.
8-K
Nasdaq delisting affirmed
Ocean Biomedical's securities face delisting from Nasdaq after the Listing Council affirmed the Hearings Panel's April 22, 2025, decision on July 17, 2025, with trading suspension effective April 24, 2025. The appeal failed despite the company's efforts. Delisting threatens liquidity and investor access. This hits hard for a biotech emerging growth company.
8-K
Licenses terminated for breaches
Ocean Biomedical's key licenses from Elkurt, Inc. terminated effective July 10, 2025, after the company failed to cure material breaches within the 30-day notice period starting June 9. The termination ends all ongoing obligations from Elkurt but preserves Ocean's accrued liabilities, including full payment of owed amounts. This strips vital intellectual property rights. Breaches hit hard.
8-K
Licenses terminated for breaches
Ocean Biomedical's key licenses from Elkurt for Brown University and RIH technologies terminated on June 9, 2025, due to uncured breaches including $612,581.16 in unpaid fees and patent costs, plus lapsed development milestones like a missed IND filing by June 30, 2024. Elkurt cited no substantive progress on product efforts. This strips the biotech of core IP, halting related R&D. Termination cascades from Brown's upstream notice.
10-Q
Q1 FY2025 results
Ocean Biomedical posted an operating loss of $0.958M for Q1 FY2025 ended March 31, 2025, up 61% y/y from $0.595M, driven by higher general and administrative costs tied to audit and SEC filings. Yet net loss swung to $8.2M from $13.0M income, as fair-value losses on the Backstop Put Option Liability and Fixed Maturity Consideration totaled $2.8M—versus $15.3M gains last year—while debt conversions added a $1.7M redemption premium and $2.6M issuance loss. No revenue yet, with R&D steady at $18K. Liquidity stays tight: zero unrestricted cash, $0.8M restricted, $9.4M short-term debt (down q/q from conversions), and a $92.4M stockholders' deficit. Debt overhang burdens progress. Nasdaq delisting looms after April 2025 notice, risking trading access.
IPO
Employees
Sector
Industry
ARCT
Arcturus Therapeutics Holdings
7.13-0.12
CBIO
Crescent Biopharma, Inc.
12.92-0.29
CLRB
Cellectar Biosciences, Inc.
3.18-0.02
GTBP
GT Biopharma, Inc.
0.72+0.09
INBX
Inhibrx Biosciences, Inc.
81.57+5.36
ORMP
Oramed Pharmaceuticals Inc.
3.08+0.00
OSRH
OSR Holdings, Inc.
0.55-0.02
OTLC
Oncotelic Therapeutics, Inc.
0.09+0.00
OVID
Ovid Therapeutics Inc.
1.55-0.01
TVRD
Tvardi Therapeutics, Inc.
4.20-0.02